EUVIMEDEUVIMED entdecken
Crossref

Platinum-Based Mcl-1 Inhibitor Targeting Mitochondria Achieves Enhanced Antitumor Activity as a Single Agent or in Combination with ABT-199

Xing Lu, Mei-Feng Wu, Jiang-Lun Wu, Hai-Qun Zhang, Hong Liang, Zhen-Feng Chen iD

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.3c00355 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Xing Lu und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medici…. Hauptthemen laut MEDLINE: Antineoplastic Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: Natural Science Foundation of Guangxi Province, State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Discovery of small molecule inhibitors targeting Mcl-1 (Myeloid cell leukemia 1) confronts many challenges. Based on the fact that Mcl-1 is mainly localized in mitochondria, we propose a new strategy of targeting mitochondria to improve the binding efficiency of Mcl-1 inhibitors. We report the discovery of complex 9, the first mitochondrial targeting platinum-based inhibitor of Mcl-1, which selectively binds to Mcl-1 with high binding affinity. Complex 9 was mainly concentrated in the mitochondria of tumor cells which led to an enhanced antitumor efficacy. Complex 9 induced Bax/Bak-dependent apoptosis in LP-1 cells and synergized with ABT-199 to kill ABT-199 resistant cells in multiple cancer models. Complex 9 was effective and tolerable as a single agent or in combination with ABT-199 in mouse models. This research work demonstrated that developing mitochondria-targeting Mcl-1 inhibitors is a new potentially efficient strategy for tumor therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsAnimalsMiceMyeloid Cell Leukemia Sequence 1 ProteinCell Line, TumorApoptosisMitochondriaProto-Oncogene Proteins c-bcl-2NitrophenolsSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Substanzen

Myeloid Cell Leukemia Sequence 1 ProteinAntineoplastic AgentsProto-Oncogene Proteins c-bcl-2NitrophenolsvenetoclaxSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovati…
  • Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair, The Affiliated Hospital of Guilin Medical University, Guilin 541001, China.
  • Guangxi Health Commission Key Laboratory of Basic Research in Sphingolipid Metabolism Related Diseases, The Affiliated Hospital of Guilin Medical University, Guilin 541001, China.

ORCID-Profile: Zhen-Feng Chen

Förderung

  • Natural Science Foundation of Guangxi Province
  • State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources
  • National Natural Science Foundation of China

Zitieren

APA

Lu, X., Wu, M. F., Wu, J. L., Zhang, H. Q., Liang, H., & Chen, Z. F. (2023). Platinum-Based Mcl-1 Inhibitor Targeting Mitochondria Achieves Enhanced Antitumor Activity as a Single Agent or in Combination with ABT-199. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c00355

Vancouver

Lu X, Wu MF, Wu JL, Zhang HQ, Liang H, Chen ZF. Platinum-Based Mcl-1 Inhibitor Targeting Mitochondria Achieves Enhanced Antitumor Activity as a Single Agent or in Combination with ABT-199. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c00355

BibTeX
@article{Lu2023,
  author = {Lu, Xing and Wu, Mei-Feng and Wu, Jiang-Lun and Zhang, Hai-Qun and Liang, Hong and Chen, Zhen-Feng},
  title = {Platinum-Based Mcl-1 Inhibitor Targeting Mitochondria Achieves Enhanced Antitumor Activity as a Single Agent or in Combination with ABT-199},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.3c00355}
}
Kostenlos starten →